Concept Life Sciences appoints Philip Payne as Chief Commercial Officer
News Oct 24, 2017
Concept Life Sciences announced it has appointed Philip Payne as Chief Commercial Officer, to support the group’s continued growth. Philip completes Concept’s leadership team, following the appointment in August of John Handley as COO.
Philip will work with Concept’s executive team and board to drive the group’s commercial strategy, leading the business development function and helping to guide the next stage of the Company’s growth. He will be responsible for managing the sales team, including identification of new service areas, geographies and markets, supporting the broadening of Concept’s reach into Europe and the US.
Philip has 27 years’ experience in managing the integration of business development in an international environment, and has gained cross-sector expertise through roles in pharma and biotech discovery as well as analytical and development services. He joins Concept from Aptuit, where he held various roles, including Vice President of Sales, and was responsible for the global business development team and strategic accounts. Prior to joining Aptuit he was Business Development Director Europe and Asia for Sterile Technologies at Catalent Pharma Solutions, and Pharmaceutical Business Development Director with Reading Scientific Services Ltd.
Michael Fort, Executive Chairman, Concept Life Sciences, said: “Philip’s experience in managing multidisciplinary, international teams across a range of industries will be a great asset as Concept’s rapid rate of expansion continues. Following on from John’s appointment as COO, Concept now has an extremely strong leadership team. We are delighted to welcome Philip to the group.”
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “I am excited to join Concept at this pivotal stage in the growth of the Company, and look forward to working with the team to meet the group’s commercial and strategic objectives.”
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE
Doctors Rely on More Than Just Data During a DiagnosisNews
Computer scientists examine how a doctor’s “gut feeling” influences how many tests they order for patientsREAD MORE